Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ANPEP | P15144 | 2/20 | 0.54 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.54 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.54 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CTSC | P53634 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | LAP3 | P28838 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311329 | 1.00 | ALPI (0.56) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL7202509 | 0.98 | L3MBTL1 (0.54) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Bromide SCHEMBL10803039 | 0.98 | L3MBTL1 (0.54) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL987969 | 0.91 | REN (0.60) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL3409209 | 0.91 | REN (0.60) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL27163859 | 0.91 | REN (0.60) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL21010316 | 0.90 | SLC15A1 (0.64) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL16994019 | 0.89 | DPP7 (0.58) | — | |
| SCHEMBL987955 | 0.89 | DPP7 (0.58) | — | |
| SCHEMBL17941646 | 0.88 | NAAA (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021060336-A1 | NOVEL CROSSLINKED ALGINIC ACID STRUCTURE | 持田製薬株式会社 | 2021-04-01 | — | — | WO | disclosed |
| US-9255062-B2 | Fatty acid derivatives for oral administration endowed with high palatability | RHEA INNOVATIONS S.R.L. (IT) | 2016-02-09 | — | — | US | disclosed |
| EP-2268605-B1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2014-06-04 | — | — | EP | disclosed |
| US-8288549-B2 | Glycine B antagonist | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20110190342-A1 | GLYCINE B ANTAGONIST | HENRICH MARKUS | 2011-08-04 | — | — | US | disclosed |
| EP-2350014-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | RHEA INNOVATIONS S.R.L. (IT) | 2011-04-28 | — | — | US | disclosed |
| EP-2268605-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PAIA- TABILITY | Berni Canani, Roberto (IT) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010037533-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA (DE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009130735-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | BERNI CANANI ROBERTO (IT) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098319-A1 | FATTY ACID DERIVATIVES FOR ORAL ADMINISTRATION ENDOWED WITH HIGH PALATABILITY | FABP2, FFAR2, VIP | ALPI 328/4885PKM 631/4885PTGS1 2679/4885 |
| US-20110190342-A1 | GLYCINE B ANTAGONIST | GRIN2B, GLRB, GRIN2A | ALPI 4486/4885PKM 2505/4885PTGS1 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.